<DOC>
	<DOCNO>NCT00452920</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray type radiation kill tumor cell . Docetaxel may make tumor cell sensitive radiation therapy . Giving docetaxel together radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose docetaxel give together radiation therapy see well work treat patient stage II , stage III , stage IV cervical cancer .</brief_summary>
	<brief_title>Docetaxel Radiation Therapy Treating Patients With Stage II , Stage III , Stage IV Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine recommend phase II dose ( RPTD ) docetaxel administer radiotherapy patient stage IIB-IVA cervical cancer . ( Phase I ) - Assess progression-free survival patient treat regimen . ( Phase II ) Secondary - Determine safety , feasibility , toxicity regimen patient . ( Phase I ) - Assess toxicity regimen RPTD patient . ( Phase II ) - Determine response patient treat regimen . ( Phase II ) OUTLINE : This phase I , nonrandomized , prospective , dose-escalation study docetaxel follow open-label phase II study . - Phase I : Patients receive docetaxel IV 30 minute day 1 . Treatment repeat weekly 6 course absence disease progression unacceptable toxicity . Patients also undergo concurrent pelvic external-beam radiotherapy ( EBRT ) daily 5 day week 5 week . Beginning 1-2 week completion EBRT , patient receive one two application intracavitary low-dose-rate brachytherapy ( LDR BT ) comprise cesium-137 . Cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . The recommended phase II dose ( RPTD ) dose MTD . - Phase II : Patients receive docetaxel RPTD , EBRT , LDR BT phase I . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 72 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma uterine cervix Locally advance ( stage IIB IVA ) disease Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL WBC ≥ 3,000/mm^3 Creatinine normal Bilirubin normal SGOT SGPT ≤ 2.5 time upper limit normal ( ULN ) alkaline phosphatase ( AP ) ≤ ULN OR AP ≤ 4 time ULN SGOT SGPT ≤ ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment No history severe allergic reaction agent contain polysorbate 80 No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude compliance study requirement No peripheral neuropathy ≥ grade 2 No HIV positivity PRIOR CONCURRENT THERAPY : More 4 week since prior unrelated therapy recover No prior chemotherapy pelvic radiotherapy No concurrent investigational agent anticancer agent therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
</DOC>